Notice of Interim Results

RNS Number : 9972X
Surgical Innovations Group PLC
02 September 2022
 

 

Surgical Innovations Group plc

("Surgical Innovations", "SI" or the "Company")

 

Notice of Interim results

Investor presentation

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that it will release its interim results for the six months ended 30 June 2022, on Wednesday 21 September 2022.

 

Investor Presentation 

David Marsh, Chief Executive Officer, and Charmaine Day, Chief Financial Officer,  will provide a live presentation relating to the interim results via the Investor Meet Company platform on Wednesday 21 September 2022 at 5:00pm BST.

 

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Surgical Innovations Group plc via:

 

https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor

 

Investors who already follow Surgical Innovations Group plc on the Investor Meet Company platform will automatically be invited.

 

 

 

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, CFO

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Rachel Hayes

 

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303






 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORZFLFBLKLBBBF
UK 100